Company Overview and News

43
Closing Bell: Sensex up over 300 pts, midcaps underperform; IT zooms, ONGC dips

2018-05-25 moneycontrol
Benchmark indices rose, driven by IT stocks, such as, Infosys and TCS on the back of a weak rupee. The IT index has gained 18 percent so far this year. The rupee has weakened by more than 7 percent so far this year, as surging crude oil prices weigh on India, the world’s third-largest importer, raising fears that soaring costs could drive up inflation and widen the trade deficit.
500325 JIPKY MS.PRE MS.PRF 531548 MS.PRG MS.PRA 534976 533207 AJANTPHARM BJJQY MS 500570 RLNIY AXB 524804 JETAIRWAYS 531335 AXBA BAJFINANCE MS.PRI FORTIS MS.PRK SOMANYCERA AUROPHARMA RELIANCE 532617 533155 BHRQY JUBLFOOD 532215 AXISBANK RIGD JBLWY BHARTIARTL 505324 TATAMOTORS MANUGRAPH 500034 IBN JPASSOCIAT 532843 AXBKY 532532 532454 VMART ICICIBANK 532331 JPINFRATEC 532174 ARBQY ZYDUSWELL TTM

0
Somany Ceramics touches 52-week low on weak Q4 numbers

2018-05-25 moneycontrol
Share price of Somany Ceramics touched 52-week low of Rs 506.30, losing 7 percent intraday Thursday on the back of weak set of numbers declared by the company for the quarter ended March 2018.
SOMANYCERA 531548

1
GAIL, MOIL, CUB, Amrutanjan results

2018-05-23 thehindubusinessline
20 Microns, Amrutanjan, Camlin Fine Sciences, Cochin Shipyard, City Union Bank, Cummins, Digjam, Elgi Rubber, GACL, GAIL India, GIPCL, Gokaldas, Granules, Honda Siel, Heldelberg, IVP, Jindal Drilling, Maharashtra Seamless, MCF, MOIL, NCC, Pidilite, Ramco Ind, Somany Ceramics, Sundaram Finance Holdings, UB, United Spirits, Xchanging and Xpro are among the 75 firms that will declare their quarter/full year results for the period ended March 2018 on Thursday.
SOMANYCERA UNITDSPR 531548 532834 532432 532210 CUB GAILY UQNTY GAILF MAHSEAMLES CAMLINFIN 500265 SBAZ

0
Company news: Somany Ceramics

2018-05-17 thehindubusinessline
Somany Ceramics has announced that the greenfield manufacturing plant of its subsidiary, Amora Ceramics Private Ltd, has commenced commercial production from Wednesday, ahead of its scheduled timeline of June end. The unit will produce 3.80 million square meters of ceramic wall tiles per annum, the company said. Shares of Somany Ceramics closed flat at ₹583.70 on the NSE.
SOMANYCERA 531548

0
Somany Ceramics Limited - Trading Window

2018-05-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOMANYCERA 531548

0
Somany Ceramics Limited - Updates

2018-05-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOMANYCERA 531548

0
Somany Ceramics#39; 1st plant in south India to be ready in December

2018-04-23 moneycontrol
Somany Ceramics' first plant in south India near Tiruchirapali in Andhra Pradesh will be commissioned in December, a senior company official said.
SOMANYCERA 531548

0
Creador-backed Vectus Industries said to plan IPO worth Rs500 crore

2018-04-17 livemint
Mumbai: Asia-focused private equity firm Creador-backed Vectus Industries Ltd, a maker of plastic storage tanks and pipes, is looking to go public and will soon file its draft prospectus for a Rs500 crore initial public offering (IPO), said two people aware of the development.
SOMANYCERA ASHIANA 523716 535322 534809 531548 PCJEWELLER REPCOHOME

0
Somany Ceramics Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOMANYCERA 531548

0
Somany Ceramics Limited - Updates

2018-03-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOMANYCERA 531548

0
Somany Ceramics Limited - Updates

2018-03-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOMANYCERA 531548

0
Somany Ceramics Limited - Updates

2018-03-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOMANYCERA 531548

0
Somany Ceramics Limited - Updates

2018-03-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOMANYCERA 531548

0
Somany Ceramics Limited - Updates

2018-03-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOMANYCERA 531548

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...